Related Experiment Video
Updated: Aug 7, 2026
Colon Ascendens Stent Peritonitis (CASP) - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 18, 2010
[Use of piperacillin-tazobactam in abdominal surgery]
Abstract:
Piperacillin/tazobactam (P/T) was used in the monotherapy of 40 patients with various inflammatory diseases of the abdominal cavity organs. P/T was administered as dropwise intravenous infusions in a single dose of 4/0.5 g 3 times a day for 5 to 17 days. In 82.5 per cent of the patients with infection of the abdominal cavity: severe postoperative purulent wounds, peritonitis of various etiology (biliary, serous-fibrinous, hemorrhagic fibrinous), postnecrotic cyst of the pancrease, abscesses of the liver and subhepatic space P/T proved to be highly efficient. The P/T monotherapy resulted in practically complete eradication of anaerobic microbes, coagulase negative staphylococci, enterobacteria and nonfermenting bacteria except for Pseudomonas aeruginosa in the inflammation foci.
Insights
Piperacillin/tazobactam (P/T) monotherapy effectively treated abdominal infections in 82.5% of patients. This antibiotic regimen eradicated most targeted bacteria, showing high efficiency in managing complex inflammatory conditions.
Area of Science:
- Infectious Diseases
- Pharmacology
- Surgical Infections
Background:
- Abdominal cavity organ inflammatory diseases present complex treatment challenges.
- Effective antimicrobial therapy is crucial for managing severe infections like peritonitis and abscesses.
- Piperacillin/tazobactam is a broad-spectrum antibiotic combination.
Purpose of the Study:
- To evaluate the efficacy of piperacillin/tazobactam (P/T) as monotherapy.
- To assess P/T's effectiveness in treating various inflammatory diseases of abdominal organs.
- To determine the impact of P/T monotherapy on microbial eradication in infection foci.
Main Methods:
- A study involving 40 patients with inflammatory abdominal conditions.
- Administration of piperacillin/tazobactam (4/0.5 g) intravenously three times daily.
- Treatment duration ranged from 5 to 17 days.
Main Results:
- Piperacillin/tazobactam demonstrated high efficiency in 82.5% of patients.
- Effective treatment was observed in cases of purulent wounds, peritonitis, pancreatic cysts, and abscesses.
- Monotherapy led to near-complete eradication of anaerobic microbes, staphylococci, enterobacteria, and nonfermenting bacteria (excluding Pseudomonas aeruginosa).
Conclusions:
- Piperacillin/tazobactam monotherapy is a highly effective treatment for various abdominal inflammatory diseases.
- P/T demonstrates significant antimicrobial activity against a broad spectrum of pathogens commonly found in abdominal infections.
- Further research may explore P/T's role in managing infections involving Pseudomonas aeruginosa.
